Tamoxifen for Breast Cancer: 162 Real Stories

162 stories match breast cancer and tamoxifen. 150 of them mention surgery.

Cancer Stories

Megan, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Megan's Survivor Story

Patient Info: Megan Claire Chase, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2 not reported

As of July 2023, Megan-Claire was in survivorship after Stage II invasive lobular breast cancer, with clear early scans but significant long-term effects, surgical menopause, chronic pain, fatigue, chemo brain, and inability to tolerate recurrence-prevention medications.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Stephanie, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Stephanie's Survivor Story

Patient Info: Stephanie, Female, 50s

Biomarkers: Oncotype DX score 7

As of July 2023, Stephanie was in ongoing survivorship after unilateral mastectomy for ILC, with no lymph node spread, no chemotherapy or radiation, and a planned 10-year tamoxifen course begun in January 2019.

Lobular Breast Cancer Alliance
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Reconstructive surgery technique fixes tissue death after mastectomy

Patient Info: Anonymized, Female

Biomarkers: Hormone receptor-positive in both breast cancers

The reconstructive wound was completely healed at 2 months, and she continued tamoxifen with ongoing follow-up.

PubMed Central
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Rare breast cancer subtype that recurred years later in a more aggressive form

Patient Info: Anonymized, Female | Stage IV

Biomarkers: CD117 focally positive in the transformed component; high Ki-67; hormone-receptor status was unknown at the original diagnosis

Metastatic Site: lungs

One year after treatment for the late chest-wall recurrence, CT showed another local recurrence and metastatic nodules in both lungs. She chose to continue treatment elsewhere.

PubMed Central
OutcomeSetback / Progression
Jodi, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Jodi's Patient Story

Patient Info: Jodi | Stage III

Jodi remained on tamoxifen after mastectomy for stage 3 breast cancer and had declined the recommended chemotherapy and radiation therapy.

Our Cancer Stories
OutcomeCare Ongoing
Bethany, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Bethany's Patient Story

Patient Info: Bethany, Female, Under 40 | Stage IV

Biomarkers: ER-positive / hormone-positive

Metastatic Site: Liver; bones; lymph nodes; stomach

As of December 2022, Bethany was living with Stage IV metastatic breast cancer after recurrence to the liver, bones, lymph nodes, and stomach, and was on lifelong maintenance treatment after disease shrinkage.

The Patient Story
OutcomeLiving With Cancer
Pam, who was diagnosed with Stage IV Breast CancerBreast Cancer

Teacher travels 600 miles for Dana-Farber care

Patient Info: Pam Zwemer, 50s | Stage IV

Metastatic Site: bone, stomach lining

11+ years after her original breast cancer diagnosis, she was living with Stage IV disease after bone recurrence in 2008 and spread to the stomach lining in 2011, while continuing clinical-trial care and working as a teacher.

Dana-Farber
OutcomeCare Ongoing
Lorena, who was diagnosed with Stage I Breast CancerBreast Cancer

Stage I Breast Cancer: Lorena's Patient Story

Patient Info: Lorena, Female | Stage I

As of April 2022, Lorena was nearly 3 years into recovery from Stage I breast cancer after double mastectomy with immediate reconstruction and ongoing tamoxifen.

MatchTrial Historias Reales
OutcomeCare Ongoing
Stephanie, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Stephanie's Patient Story

Patient Info: Stephanie, Female, 60s

As of February 2022, Stephanie was living with locoregional recurrent ILC after extensive surgery and ongoing treatment with Ibrance/Femara, with recent bone, abdomen, and chest scans showing no new cancer growth and continued Femara without chemotherapy.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
Yurley, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Yurley's Survivor Story

Patient Info: Yurley, Under 40 | Stage III

She reports that her breast cancer is in remission and that she continues hormone therapy.

Our Cancer Stories
OutcomeCancer-Free / NED
Katie, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Katie's Survivor Story

Patient Info: Katie, Female, Under 40 | Stage III

Biomarkers: Hormone-sensitive breast cancer; specific receptor results not otherwise reported

As of December 2021, Katie had no evidence of cancer at the 5-year treatment mark after Stage III hormone-sensitive breast cancer treatment and later had twins after ovarian function returned.

Cleveland Clinic
OutcomeCancer-Free / NED
Jacque, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III Invasive Lobular Carcinoma: Jacque's Patient Story

Patient Info: Jacque, Female | Stage III

Jacque was treated for Stage III ILC with chemotherapy, 2 lumpectomies, daily radiation, and ongoing Tamoxifen as of December 2021.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
Martha, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III Invasive Lobular Carcinoma: Martha's Survivor Story

Patient Info: Martha, Female, 40s | Stage III

Martha completed chemotherapy, bilateral mastectomies and 30 radiation treatments and remained on Tamoxifen as part of a planned 10-year course.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing / Survivorship
Brian, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Brian's Patient Story

Patient Info: Brian Chrobak, Male, Under 40

Biomarkers: Hormone receptor-positive

Brian had completed neoadjuvant chemotherapy and surgery and was preparing to begin radiation and hormone therapy with curative intent. Tests showed no evidence of spread beyond the breast and axillary lymph nodes.

Cleveland Clinic
OutcomeLiving With Cancer / Ongoing Treatment
MB
Breast Cancer

Male breast cancer discovered after years of stiff-person syndrome

Patient Info: Anonymized, Male, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative; anti-amphiphysin antibody positive at 1:64; hereditary cancer panel negative for pathogenic germline variants.

He completed curative-intent breast cancer treatment and reported substantial improvement in upper-body stiffness, although lower-extremity stiffness, cramps, and unsteadiness persisted.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast cancer recurrence in the mandibular condyle causing jaw pain

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative.

Metastatic Site: right mandibular condyle with extension into the…

After anastrozole and 60 Gy of radiation, her jaw pain, mouth opening, and function improved, although some discomfort remained and palliative systemic treatment was continuing.

PubMed Central
OutcomeResponding Well
LA
Breast Cancer

Locally advanced male breast cancer associated with a pathogenic ATM variant

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: ER 100% positive; PR 100% positive; HER2-negative; Ki-67 30%; germline pathogenic ATM variant c.2921+1G>A.

Two years after diagnosis, he had an ECOG performance status of 0 and remained without signs of breast-cancer relapse or another primary cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

A durable response to trastuzumab in heavily pretreated metastatic breast cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor ER-positive and PR-positive. Metastatic liver biopsy ER-negative and PR-negative with HER2 IHC 1+ and nonamplified. Later biopsy ER and PR weakly positive at 5%–10%, HER2 IHC 1+ and nonamplified, and ERBB3 p. with evidence of HER2/HER3 pathway activation.

Metastatic Site: lungs; hilar and mediastinal lymph nodes; liver; bone

She had ongoing benefit for more than 10 months on trastuzumab and capecitabine, with improved symptoms, lower tumor markers, and a confirmed partial response.

PubMed Central
OutcomeResponding Well
Alexandra, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Alexandra's Patient Story

Patient Info: Alexandra, Female, 40s | Stage III

As of 2021, Alexandra was living with Stage III breast cancer and continuing chemotherapy after treatment with docetaxel, carboplatin, antibody drug conjugates, and tamoxifen.

Our Cancer Stories
OutcomeCare Ongoing
Ana, who was diagnosed with Stage II Breast CancerBreast Cancer

Ana's Stage 2 Breast Cancer and Cancer-Free Milestone

Patient Info: Ana, Female, 50s | Stage II

Ana completed intensive multimodal treatment and was declared cancer-free in 2024. She continued Tamoxifen as a planned 5-year hormone-therapy course.

Our Cancer Stories
OutcomeCancer-Free / NED